Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide
high-quality cGMP quaternary ammonium compounds in twelve countries
across Asia Pacific.
Koege, Denmark, January 16th, 2019 – DKSH’s Business Unit
Performance Materials, a leading ingredients and specialty chemicals
distributor, will distribute Novo Nordisk Pharmatech’s pharmaceutical
grade compounds (quats) to its large customer base in Australia, New
Zealand, Vietnam, Japan, Indonesia, South Korea, Thailand, Malaysia,
Philippines, China, Taiwan and Singapore.
Novo Nordisk Pharmatech manufactures its pharmaceutical quats in
accordance with the cGMP Guide ICH Q7 for Active Pharmaceutical
Ingredients (APIs), the highest available quality standard in the
industry. The quats, Benzalkonium Chloride (BKC), Cetrimonium Bromide
(CTAB), Cetrimide and Strong Cetrimide, act either as preservatives or
active ingredients in a diverse range of applications, including
ophthalmic, nasal, oral, dental or topical treatments and medical
devices, such as wound care.
DKSH was chosen for its proven experience in providing Market
Expansion Services along the entire value chain and its solid logistics
infrastructure. As a regional expert with more than 150 years of
experience in the Asian markets, DKSH offers an omni-channel approach
that presents a one-stop regional solution for its clients. DKSH
provides tailored valued-added services and a deep capillary
distribution network that will enable the distribution of Novo Nordisk’s
products in the twelve markets across Asia Pacific.
Tanja Schaffer, Vice President, Global Pharmaceutical Industry,
DKSH, commented: “We are very pleased to partner with Novo Nordisk
Pharmatech in Asia Pacific. Their pharmaceutical grade quats are a
perfect fit for our API portfolio. We look forward to providing the
quats to our large customer base in the region and to building a
prosperous relationship with Novo Nordisk Pharmatech.”
Steve Profit, Global Sales & Marketing Director at Novo Nordisk
Pharmatech A/S, added: “For Novo Nordisk Pharmatech it is critical that
we have a distribution partner that shares our business ethics and
drive to offer the best services to our customers, so we are delighted
to have DKSH as our new distribution partner. Novo Nordisk Pharmatech’s
FeF® GMP quats products fit perfectly with DKSH’s wide range of
excipients, enabling the customers to take advantage of these synergies.
Together, we will be able to offer the best quality and local
distribution in the market. This will allow our customers to grow in
this progressing global market.”
About Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S was established in 1949 as FeF
Chemicals, acquired by Novo Nordisk in 1986 and has been part of the
pharmaceutical group since then. Novo Nordisk Pharmatech A/S is the
leading worldwide supplier of recombinant insulin for cell growth media
and pharmaceutical grade quaternary ammonium compounds (quats) for the
pharmaceutical, biopharmaceutical industry.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus
on Asia. As the term "Market Expansion Services" suggests, DKSH helps
other companies and brands to grow their business in new or existing
markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a
global company headquartered in Zurich. With 825 business locations in
37 markets – 800 of them in Asia – and 31,970 specialized staff, DKSH
generated net sales of CHF 11.0 billion in 2017. DKSH was founded in
1865. With strong Swiss heritage, the company has a long tradition of
doing business in and with Asia and is deeply rooted in communities and
businesses across Asia Pacific.
DKSH Business Unit Performance Materials is a leading
specialty chemicals distributor and provider of Market Expansion
Services for performance materials, covering Europe, North America and
the whole of Asia. The Business Unit sources, develops, markets and
distributes a wide range of specialty chemicals and ingredients for
pharmaceutical, personal care, food & beverage as well as various
industrial applications. In addition, it creates innovative and
cutting-edge concepts and applications in 29 innovation centers located
worldwide. With 100 business locations in 31 markets and around 1,010
specialized staff, Business Unit Performance Materials generated net
sales of CHF 894.1 million in 2017.
For further information, please contact:
DKSH Performance Materials
Daniel Hollister
Manager, Group Communications, Performance Materials
Phone +44 20 8879 5500
daniel.hollister@dksh.com
Novo Nordisk Pharmatech A/S
Vanessa León Toft
Marketing Manager
Phone +45 5667 1000
vnlt@novonordiskpharmatech.com
